1 hr. ago
The iconic skyline of Milan is set for a historic transformation as the city's two footballing heavyweights prepare to move into a state-of-the-art new home. In a move that signals a massive shift in the financial landscape of Serie A, AC Milan and Inter have officially secured a record-breaking naming rights partnership with Italian insurance giant Generali for their future shared arena.
Milan and Inter have agreed a staggering 20-year naming rights contract with Generali, which ESPN reports is worth €650 million (£545m/$725m). The new 71,500-capacity venue will be officially known as the Generali Stadium, effectively replacing the historic San Siro. The clubs purchased the required land from the city last November for €197m, paving the way for the eventual demolition of their legendary current home.
Construction is targeted to begin in 2028, with the first matches scheduled for the 2031-32 campaign, pending necessary approvals. Spearheaded by respective ownership groups RedBird Capital Partners and Oaktree, the stadium project also anchors a wider urban regeneration plan featuring new retail, leisure, and green ******* es.
The massive financial commitment eclipses the $700m agreement struck by Crypto.com in 2021 for the Los Angeles arena shared by the Lakers and Kings. It stands as a monumental boost for the two Serie A giants as they look to modernise and bridge the matchday revenue gap with Europe's elite.
A new symbol for Milano.
A new home for future generations of fans.
Generali Stadium 🏟️GENERALI pic.twitter.com/c7D0827E7T
#generali #historic
Milan and Inter have agreed a staggering 20-year naming rights contract with Generali, which ESPN reports is worth €650 million (£545m/$725m). The new 71,500-capacity venue will be officially known as the Generali Stadium, effectively replacing the historic San Siro. The clubs purchased the required land from the city last November for €197m, paving the way for the eventual demolition of their legendary current home.
Construction is targeted to begin in 2028, with the first matches scheduled for the 2031-32 campaign, pending necessary approvals. Spearheaded by respective ownership groups RedBird Capital Partners and Oaktree, the stadium project also anchors a wider urban regeneration plan featuring new retail, leisure, and green ******* es.
The massive financial commitment eclipses the $700m agreement struck by Crypto.com in 2021 for the Los Angeles arena shared by the Lakers and Kings. It stands as a monumental boost for the two Serie A giants as they look to modernise and bridge the matchday revenue gap with Europe's elite.
A new symbol for Milano.
A new home for future generations of fans.
Generali Stadium 🏟️GENERALI pic.twitter.com/c7D0827E7T
#generali #historic
1 month ago
Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on each other's data, the reading carries far more weight than Definium's own ticker.
On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.
The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."
Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.
That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.
#definium #placebo
On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.
The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."
Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.
That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.
#definium #placebo
2 months ago
When U.S. Treasury Secretary Scott Bessent claimed recently that interest rates have fallen since President Donald Trump's 2025 inauguration, there's some generalization there that needs to be unpacked.
Here's the yield curve on Jan. 20, 2025, Inauguration Day. And the curve as it existed on Aug. 31, 2026.
Why It's Time to Load Up on SoFi Stock
A $1.4 Billion Reason to Buy GameStop Stock Now
TIME Left Nvidia CEO Jensen Huang Off Its 100 Most Influential People in AI List — But Paris Hilton and Ben Affleck Made the Cut
#curve
Here's the yield curve on Jan. 20, 2025, Inauguration Day. And the curve as it existed on Aug. 31, 2026.
Why It's Time to Load Up on SoFi Stock
A $1.4 Billion Reason to Buy GameStop Stock Now
TIME Left Nvidia CEO Jensen Huang Off Its 100 Most Influential People in AI List — But Paris Hilton and Ben Affleck Made the Cut
#curve
2 months ago
On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven's lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven's Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines up with an August 10, 2026 earnings report that showed Biohaven still losing well over $100 million a quarter, and the gap between those two dates explains a lot about why this deal happened now.
SK Biopharmaceuticals will pay up to $795 million in upfront and milestone payments connected to the Kv7 platform, on top of tiered royalties on US net sales of opakalim that range from the mid-teens to low twenties. Biohaven collects $350 million at closing and another $50 million in 2027, with as much as $150 million more available through development and regulatory milestones plus royalties on global sales. SK Biopharmaceuticals is also taking over Kv7 program costs going forward, including certain Knopp Biosciences obligations. CEO Vlad Coric described the structure as proof Biohaven can monetize its pipeline through partnerships rather than leaning on public markets for cash.
The deal only makes sense because opakalim looks like it works. In a proof-of-concept study in idiopathic generalized epilepsy, the median time to a second generalized tonic-clonic seizure stretched to 141 days on opakalim versus 47 days on placebo, and a third of patients made it through the full 24 weeks without a second seizure. In focal epilepsy, 54% of patients in an open-label extension study saw at least a 50% drop in seizure frequency over any six months, in a group of more than 100 patients.
Opakalim is also designed as a once-daily pill with no ******* ration required, a real edge over older antiseizure drugs. Pairing that data with SK Biopharmaceuticals, the company behind XCOPRI and the only firm to bring a new focal-seizure drug to the US market since 2016, gives Opakalim a commercial path Biohaven would have struggled to build alone. The cash also buys runway for the rest of the pipeline, including protein degraders BHV-1300 and BHV-1400, which have shown rapid, selective reductions in disease-driving antibodies in Graves' disease and IgA nephropathy with clean safety data across nearly 200 patients dosed.
Biohaven is giving up full ownership of an ******* et it now believes could be a major seller. Royalties in the mid-teens to low twenties are real money, but they are a fraction of what outright ownership of an approved epilepsy drug would be worth, and $50 million of the $400 million upfront does not arrive until 2027. The Knopp Biosciences obligations SK Biopharmaceuticals is absorbing, worth up to $245 million plus mid-single-digit royalties, are a reminder that other parties already have claims on opakalim's future revenue before Biohaven sees a dollar of profit from it.
#ro
SK Biopharmaceuticals will pay up to $795 million in upfront and milestone payments connected to the Kv7 platform, on top of tiered royalties on US net sales of opakalim that range from the mid-teens to low twenties. Biohaven collects $350 million at closing and another $50 million in 2027, with as much as $150 million more available through development and regulatory milestones plus royalties on global sales. SK Biopharmaceuticals is also taking over Kv7 program costs going forward, including certain Knopp Biosciences obligations. CEO Vlad Coric described the structure as proof Biohaven can monetize its pipeline through partnerships rather than leaning on public markets for cash.
The deal only makes sense because opakalim looks like it works. In a proof-of-concept study in idiopathic generalized epilepsy, the median time to a second generalized tonic-clonic seizure stretched to 141 days on opakalim versus 47 days on placebo, and a third of patients made it through the full 24 weeks without a second seizure. In focal epilepsy, 54% of patients in an open-label extension study saw at least a 50% drop in seizure frequency over any six months, in a group of more than 100 patients.
Opakalim is also designed as a once-daily pill with no ******* ration required, a real edge over older antiseizure drugs. Pairing that data with SK Biopharmaceuticals, the company behind XCOPRI and the only firm to bring a new focal-seizure drug to the US market since 2016, gives Opakalim a commercial path Biohaven would have struggled to build alone. The cash also buys runway for the rest of the pipeline, including protein degraders BHV-1300 and BHV-1400, which have shown rapid, selective reductions in disease-driving antibodies in Graves' disease and IgA nephropathy with clean safety data across nearly 200 patients dosed.
Biohaven is giving up full ownership of an ******* et it now believes could be a major seller. Royalties in the mid-teens to low twenties are real money, but they are a fraction of what outright ownership of an approved epilepsy drug would be worth, and $50 million of the $400 million upfront does not arrive until 2027. The Knopp Biosciences obligations SK Biopharmaceuticals is absorbing, worth up to $245 million plus mid-single-digit royalties, are a reminder that other parties already have claims on opakalim's future revenue before Biohaven sees a dollar of profit from it.
#ro
2 months ago
Mo Zohourian turned to AI training when he couldn't land a traditional 9-to-5.
He started on generalist projects at $15/hour and now makes $100/hour as a sales specialist.
Even though he had 15 years experience in sales, Zohourian said his AI career has grown much faster.
This is an as-told-essay based on a conversation with Mo Zohourian, who works as a contractor for AI training companies, specializing in sales management. His work and project rates have been confirmed by Business Insider. Zohourian also consults on AI for small businesses and founded Annotation Academy, an educational platform for AI training. This story has been edited for length and clarity.
I moved to Canada from Iran in 2023 and started searching for jobs. I had 15 years of experience in entrepreneurship and sales management, but after back-to-back interviews, I was not getting hired.
#sales #training #hour #management
He started on generalist projects at $15/hour and now makes $100/hour as a sales specialist.
Even though he had 15 years experience in sales, Zohourian said his AI career has grown much faster.
This is an as-told-essay based on a conversation with Mo Zohourian, who works as a contractor for AI training companies, specializing in sales management. His work and project rates have been confirmed by Business Insider. Zohourian also consults on AI for small businesses and founded Annotation Academy, an educational platform for AI training. This story has been edited for length and clarity.
I moved to Canada from Iran in 2023 and started searching for jobs. I had 15 years of experience in entrepreneurship and sales management, but after back-to-back interviews, I was not getting hired.
#sales #training #hour #management
2 months ago
MUMBAI, Aug 19 (Reuters) - India's rate panel left the door open to future rate hikes earlier this month, watching for evidence that supply-sparked inflation may be seeping into the broader economy which could merit higher borrowing costs, minutes of the committee's meeting released on Wednesday showed.
A sharp rise in oil prices brought on by the Iran war has stoked inflation worries, prompting markets to wager on rate hikes, while also exerting pressure on the Indian rupee.
The panel had voted unanimously to keep the policy repo rate (INREPO=ECI) unchanged at 5.25% on August 5, while retaining its monetary policy stance at "neutral".
India's headline consumer inflation remained well within the central bank's 2-6% tolerance band at 4.45% in July. The Reserve Bank of India has a 4% medium term target.
While there are limited signs of inflation becoming generalized so far, headline inflation does appear to be normalizing "from its benign levels seen hitherto," RBI Chief Sanjay Malhotra said in the minutes.
#inflation
A sharp rise in oil prices brought on by the Iran war has stoked inflation worries, prompting markets to wager on rate hikes, while also exerting pressure on the Indian rupee.
The panel had voted unanimously to keep the policy repo rate (INREPO=ECI) unchanged at 5.25% on August 5, while retaining its monetary policy stance at "neutral".
India's headline consumer inflation remained well within the central bank's 2-6% tolerance band at 4.45% in July. The Reserve Bank of India has a 4% medium term target.
While there are limited signs of inflation becoming generalized so far, headline inflation does appear to be normalizing "from its benign levels seen hitherto," RBI Chief Sanjay Malhotra said in the minutes.
#inflation
3 months ago
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted argenx SE (NASDAQ:ARGX). argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the United States and internationally. On August 03, 2026, argenx SE (NASDAQ:ARGX) closed at $830.79 per share. The one-month return of argenx SE (NASDAQ:ARGX) was -9.69% and its shares gained 23.10% over the past 52 weeks. argenx SE (NASDAQ:ARGX) has a market capitalization of $51.66 billion with a 52-week trading range between $631.47 - $953.58.
Baron Health Care Fund stated the following regarding argenx SE (NASDAQ:ARGX) in its Q2 2026 investor letter:
"Biotechnology company argenx SE (NASDAQ:ARGX) is best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose after a period of prior weakness, which may have been partly driven by the retirement of longtime CEO Tim Van Hauwermeiren in early 2026. We view the transition to Karen Massey, who previously led the company's operations, as largely non-disruptive and believe she is well positioned to continue executing the company's strategy. Shares also benefited from optimism ahead of several clinical readouts, including data from studies of Vyvgart in immune-mediated necrotizing myopathy and dermatomyositis, expected in the third quarter of 2026, as well as empasibrupart in multifocal motor neuropathy, expected in the fourth quarter of 2026. Vyvgart continues to launch well in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, where we believe it has established itself as an important treatment option. We expect Vyvgart to demonstrate efficacy across an expanding range of autoantibody-driven autoimmune conditions over time and remain encouraged by argenx's pipeline progress."
#care #argx #baron #vyvgart
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted argenx SE (NASDAQ:ARGX). argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the United States and internationally. On August 03, 2026, argenx SE (NASDAQ:ARGX) closed at $830.79 per share. The one-month return of argenx SE (NASDAQ:ARGX) was -9.69% and its shares gained 23.10% over the past 52 weeks. argenx SE (NASDAQ:ARGX) has a market capitalization of $51.66 billion with a 52-week trading range between $631.47 - $953.58.
Baron Health Care Fund stated the following regarding argenx SE (NASDAQ:ARGX) in its Q2 2026 investor letter:
"Biotechnology company argenx SE (NASDAQ:ARGX) is best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose after a period of prior weakness, which may have been partly driven by the retirement of longtime CEO Tim Van Hauwermeiren in early 2026. We view the transition to Karen Massey, who previously led the company's operations, as largely non-disruptive and believe she is well positioned to continue executing the company's strategy. Shares also benefited from optimism ahead of several clinical readouts, including data from studies of Vyvgart in immune-mediated necrotizing myopathy and dermatomyositis, expected in the third quarter of 2026, as well as empasibrupart in multifocal motor neuropathy, expected in the fourth quarter of 2026. Vyvgart continues to launch well in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, where we believe it has established itself as an important treatment option. We expect Vyvgart to demonstrate efficacy across an expanding range of autoantibody-driven autoimmune conditions over time and remain encouraged by argenx's pipeline progress."
#care #argx #baron #vyvgart
3 months ago
These are unprecedented times, with companies pumping hundreds of billions of dollars into capital expenditures -- data centers, GPUs, and other infrastructure for artificial intelligence (AI). It's an arms race of sorts, and companies are spending first and asking questions later in fear of missing out on their share of AI adoption.
Two groups of AI stocks have formed within this capex boom. On one side are the AI hyperscalers, big tech companies like Microsoft, Amazon, Meta Platforms, and Alphabet. On the other side are neoclouds, companies such as CoreWeave (NASDAQ: CRWV) and Nebius Group (NASDAQ: NBIS), that build specialized GPU data centers and sell the computing power.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Knowing which group actually wins in the big picture is crucial to deciding where to invest your dollars.
Neocloud companies build specialized GPU data centers, engineered from the ground up for AI workloads. That specialization gives them cost advantages over hyperscalers building more generalized data centers for a broader range of applications. The rampant demand for AI compute is fueling blistering growth at neocloud companies such as CoreWeave and Nebius, where ***** ysts expect revenue to multiply over the next couple of years.
#coreweave #NASDAQ #nebius
Two groups of AI stocks have formed within this capex boom. On one side are the AI hyperscalers, big tech companies like Microsoft, Amazon, Meta Platforms, and Alphabet. On the other side are neoclouds, companies such as CoreWeave (NASDAQ: CRWV) and Nebius Group (NASDAQ: NBIS), that build specialized GPU data centers and sell the computing power.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Knowing which group actually wins in the big picture is crucial to deciding where to invest your dollars.
Neocloud companies build specialized GPU data centers, engineered from the ground up for AI workloads. That specialization gives them cost advantages over hyperscalers building more generalized data centers for a broader range of applications. The rampant demand for AI compute is fueling blistering growth at neocloud companies such as CoreWeave and Nebius, where ***** ysts expect revenue to multiply over the next couple of years.
#coreweave #NASDAQ #nebius
4 months ago
WASHINGTON (AP) — President Donald Trump on Sunday posted a falsified image of former President Barack Obama and his wife, Michelle Obama, waving before boarding an Air Force One that had been spray-painted with graffiti.
It came months after another racist post by the president that showed the couple as primates in a jungle. That one was deleted after stiff, bipartisan backlash.
The latest image shows the Obamas smiling and waving at the top of stairs alongside a baby blue and white presidential plane with graffiti painted on it that included the Democrat's campaign slogan "Yes We Can," "Obama" and "BLM," short for Black Lives Matter. The post also shows graffiti in Arabic on the plane that says the phrase "alhamdulillah," which means "praise be to God" or "thank God."
The use of graffiti is a coded message to remind people of crime and urban decay and has been used in racist messaging against Black people in the past.
Trump has a yearslong record of intensely personal criticism of the Obamas, and of using incendiary, sometimes racist, rhetoric. That includes everything from feeding the lie that Obama was not born in the United States to crude generalizations about majority-Black countries and posts that have sparked anger on his Truth Social website.
It came months after another racist post by the president that showed the couple as primates in a jungle. That one was deleted after stiff, bipartisan backlash.
The latest image shows the Obamas smiling and waving at the top of stairs alongside a baby blue and white presidential plane with graffiti painted on it that included the Democrat's campaign slogan "Yes We Can," "Obama" and "BLM," short for Black Lives Matter. The post also shows graffiti in Arabic on the plane that says the phrase "alhamdulillah," which means "praise be to God" or "thank God."
The use of graffiti is a coded message to remind people of crime and urban decay and has been used in racist messaging against Black people in the past.
Trump has a yearslong record of intensely personal criticism of the Obamas, and of using incendiary, sometimes racist, rhetoric. That includes everything from feeding the lie that Obama was not born in the United States to crude generalizations about majority-Black countries and posts that have sparked anger on his Truth Social website.
4 months ago
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds.
On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with "generalized myasthenia gravis" who are anti-acetylcholine receptor antibody-positive.
The company said the FDA granted "Priority Review" for the new drug application and set a target action date in November 2026 after the use of a priority review voucher. The biotech firm also expects a European Commission decision in the second half of 2027. The filings are supported by data from the Phase 3 NIMBLE trial ****** sing subcutaneous cemdisiran dosed every 12 weeks in adults with symptomatic gMG.
On the same day, RBC Capital maintained a "Sector Perform" rating and a $707 price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). However, the firm called AbbVie's acquisition of Apogee Therapeutics a "net negative" for the company. RBC Capital said the deal adds fuel to a potential next-generation competitor to Dupixent. It also adds AbbVie's commercial expertise and longstanding dermatology market relationships behind Apogee's IL-13 antibody program.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology firm. Its brand lineup includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with "generalized myasthenia gravis" who are anti-acetylcholine receptor antibody-positive.
The company said the FDA granted "Priority Review" for the new drug application and set a target action date in November 2026 after the use of a priority review voucher. The biotech firm also expects a European Commission decision in the second half of 2027. The filings are supported by data from the Phase 3 NIMBLE trial ****** sing subcutaneous cemdisiran dosed every 12 weeks in adults with symptomatic gMG.
On the same day, RBC Capital maintained a "Sector Perform" rating and a $707 price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). However, the firm called AbbVie's acquisition of Apogee Therapeutics a "net negative" for the company. RBC Capital said the deal adds fuel to a potential next-generation competitor to Dupixent. It also adds AbbVie's commercial expertise and longstanding dermatology market relationships behind Apogee's IL-13 antibody program.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology firm. Its brand lineup includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
4 months ago
Capital One Financial Corporation (NYSE:COF) is one of the most undervalued NYSE stocks to invest in. On June 16, Capital One Software, the B2B technology and data-management division of Capital One Financial, launched Databolt Connect, a new application on the Databricks Marketplace designed to facilitate secure, multi-party data collaboration. The tool enables organizations, particularly in fields like Health and Life Sciences, to link sensitive datasets for research and ***** ytics while maintaining strict privacy and regulatory compliance.
The application operates within a zero-trust, native Databricks environment, ensuring that raw, sensitive data never leaves a customer's control. It features customizable tokenization and data generalization (such as converting full dates or ZIP codes into protected formats), which supports HIPAA de-identification workflows and allows for secure record linking between multiple parties within Databricks Clean Rooms.
By providing a way to ***** yze data without exposing identifiers to third parties, Databolt Connect aims to help enterprises balance the need for innovation with security requirements. The solution is part of Capital One Software's broader efforts to help organizations scale data management and AI capabilities in the cloud.
Capital One Financial Corporation (NYSE:COF) is a financial services company that provides various financial products and services through three segments: Credit Card, Consumer Banking, and Commercial Banking.
While we acknowledge the potential of COF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
The application operates within a zero-trust, native Databricks environment, ensuring that raw, sensitive data never leaves a customer's control. It features customizable tokenization and data generalization (such as converting full dates or ZIP codes into protected formats), which supports HIPAA de-identification workflows and allows for secure record linking between multiple parties within Databricks Clean Rooms.
By providing a way to ***** yze data without exposing identifiers to third parties, Databolt Connect aims to help enterprises balance the need for innovation with security requirements. The solution is part of Capital One Software's broader efforts to help organizations scale data management and AI capabilities in the cloud.
Capital One Financial Corporation (NYSE:COF) is a financial services company that provides various financial products and services through three segments: Credit Card, Consumer Banking, and Commercial Banking.
While we acknowledge the potential of COF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
5 months ago
Barcelona’s ambition to host the 2029 UEFA Champions League final at the Spotify Camp Nou is entering its decisive phase, with the club racing to complete all documentation ahead of this Wednesday’s submission deadline.
According to Mundo Deportivo, Barcelona are finalising the details of their official bid dossier and plan to submit it to UEFA either on Tuesday or Wednesday.
Their bid is backed by the support of the Spanish Government, the Generalitat of Catalonia, the Barcelona City Council and the RFEF.
The full Camp Nou project is still yet to be completed. (Photo by Alex Caparros/Getty Images)
Barring any surprises, the competition for the 2029 final appears to have narrowed to two candidates – the Spotify Camp Nou and London’s Wembley Stadium.
According to Mundo Deportivo, Barcelona are finalising the details of their official bid dossier and plan to submit it to UEFA either on Tuesday or Wednesday.
Their bid is backed by the support of the Spanish Government, the Generalitat of Catalonia, the Barcelona City Council and the RFEF.
The full Camp Nou project is still yet to be completed. (Photo by Alex Caparros/Getty Images)
Barring any surprises, the competition for the 2029 final appears to have narrowed to two candidates – the Spotify Camp Nou and London’s Wembley Stadium.
11 months ago
US stocks rose during a holiday-shortened trading day on Friday as a volatile month drew to a close and the Nasdaq Composite (^IXIC) snapped a seven-month win streak.
The tech-heavy Nasdaq Composite (^IXIC) and blue-chip Dow Jones Industrial Average (^DJI) led the market higher on Black Friday, gaining around 0.6%. The generalist S&P 500 (^GSPC) rose by 0.5%, marking the fifth straight day of gains for the major indexes.
Stocks rebounded sharply this week as traders ramped up bets that the Federal Reserve will cut interest rates at its meeting in December, less than two weeks away. Renewed f
The tech-heavy Nasdaq Composite (^IXIC) and blue-chip Dow Jones Industrial Average (^DJI) led the market higher on Black Friday, gaining around 0.6%. The generalist S&P 500 (^GSPC) rose by 0.5%, marking the fifth straight day of gains for the major indexes.
Stocks rebounded sharply this week as traders ramped up bets that the Federal Reserve will cut interest rates at its meeting in December, less than two weeks away. Renewed f
11 months ago
US stocks rose during a holiday-shortened trading day on Friday as a volatile month drew to a close and the Nasdaq Composite (^IXIC) snapped a seven-month win streak.
The tech-heavy Nasdaq Composite (^IXIC) and blue-chip Dow Jones Industrial Average (^DJI) led the market higher on Black Friday, gaining around 0.6%. The generalist S&P 500 (^GSPC) rose by 0.5%, marking the fifth straight day of gains for the major indexes.
Stocks rebounded sharply this week as traders ramped up bets that the Federal Reserve will cut interest rates at its meeting in December, less than two weeks away. Renewed f
The tech-heavy Nasdaq Composite (^IXIC) and blue-chip Dow Jones Industrial Average (^DJI) led the market higher on Black Friday, gaining around 0.6%. The generalist S&P 500 (^GSPC) rose by 0.5%, marking the fifth straight day of gains for the major indexes.
Stocks rebounded sharply this week as traders ramped up bets that the Federal Reserve will cut interest rates at its meeting in December, less than two weeks away. Renewed f
